Engineered immune cells take on childhood leukemia and lymphoma in landmark trial
NCT ID NCT02625480
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 30 times
Summary
This study tested a treatment called KTE-X19, a type of CAR T-cell therapy, in 95 children and adolescents whose B-cell acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) had returned or stopped responding to standard treatments. The therapy involves collecting a patient's own immune cells, reprogramming them to attack cancer, and infusing them back after a short course of chemotherapy. The goal was to see if the treatment is safe and can shrink or eliminate the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ann & Robert H. Lurie Children's Hospital
Chicago, Illinois, 60611, United States
-
Bambino Gesù Children's Hospital
Rome, 00165, Italy
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Children's Hospital of Orange County
Orange, California, 92868, United States
-
Children's Hospitals and Clinics of Minnesota
Minneapolis, Minnesota, 55404, United States
-
Columbia University Irving Medical Center/Morgan Stanley Children's Hospital-NYP
New York, New York, 10032, United States
-
Hopital Robert Debre - Sevice d'Hemato-immunologic
Paris, 75935, France
-
Hopital d'Enfants la Timone
Marseille, 13385, France
-
Hospital Sant Joan de Déu
Barcelona, 08950, Spain
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Institut d'Hematologie et Oncologie Pediatrique
Lyon, 69373, France
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
-
Jurasz University Hospital 1; Collegium Medicum
Bydgoszcz, 85-094, Poland
-
Kapi'olani Medical Center for Women and Children
Honolulu, Hawaii, 96826, United States
-
Karolinska University Hospital
Stockholm, SE-141 86, Sweden
-
Monroe-Carell Jr. Children's Hospital at Vanderbilt
Nashville, Tennessee, 37232, United States
-
Prinses Maxima Centrum
Utrecht, 3508, Netherlands
-
Texas Children's Hospital
Houston, Texas, 77030, United States
-
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
The Hospital for Sick Children
Toronto, M5G 1X8, Canada
-
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
UCSF Benioff Children's Hospital
San Francisco, California, 94158, United States
-
Unité d'Oncologie et Hématologie Pédiatriques
Bordeaux, 33 000, France
-
University Hospital Brno
Brno, 625 00, Czechia
-
University Hospital Gent
Ghent, 9000, Belgium
-
University Medical Center Hamburg-Eppendorf (UKE)
Hamburg, 20246, Germany
-
University of Miami Hospital & Clinics
Miami, Florida, 33136, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
-
University of Virginia Health System, Pediatric Hematology/Oncology Clinic
Charlottesville, Virginia, 22908, United States
-
Wroclaw Medical University
Wroclaw, 50-556, Poland
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Brexucabtagene autoleucel (KTE-X19), a CAR T-cell therapy made from the patient's own immune cells, given with chemotherapy drugs fludarabine and cyclophosphamide
What this could lead to
If successful, this could offer a powerful treatment option for children and teens with hard-to-treat leukemia or lymphoma that has come back or not responded to standard therapy.
What could go wrong
This is an early-phase trial (phase 1/2) with a small number of participants, so results may not apply to everyone. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and nervous system problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.